Decreased binding of [11C]flumazenil in Angelman syndrome patients with GABAA receptor β3 subunit deletions

IE Holopainen, EL Metsähonkala… - Annals of Neurology …, 2001 - Wiley Online Library
IE Holopainen, EL Metsähonkala, H Kokkonen, RK Parkkola, TE Manner, K Någren…
Annals of Neurology: Official Journal of the American Neurological …, 2001•Wiley Online Library
We used positron emission tomography (PET) to study brain [11C] flumazenil (FMZ) binding
in four Angelman syndrome (AS) patients. Patients 1 to 3 had a maternal deletion of 15q11‐
q13 leading to the loss of β3 subunit of γ‐aminobutyric acidA/benzodiazepine (GABAA/BZ)
receptor, whereas Patient 4 had a mutation in the ubiquitin protein ligase (UBE3A) saving
the β3 subunit gene.[11C] FMZ binding potential in the frontal, parietal, hippocampal, and
cerebellar regions was significantly lower in Patients 1 to 3 than in Patient 4. We propose …
Abstract
We used positron emission tomography (PET) to study brain [11C]flumazenil (FMZ) binding in four Angelman syndrome (AS) patients. Patients 1 to 3 had a maternal deletion of 15q11‐q13 leading to the loss of β3 subunit of γ‐aminobutyric acidA/benzodiazepine (GABAA/BZ) receptor, whereas Patient 4 had a mutation in the ubiquitin protein ligase (UBE3A) saving the β3 subunit gene. [11C]FMZ binding potential in the frontal, parietal, hippocampal, and cerebellar regions was significantly lower in Patients 1 to 3 than in Patient 4. We propose that the 15q11‐q13 deletion leads to a reduced number of GABAA/BZ receptors, which could partly explain the neurological deficits of the AS patients. Ann Neurol 2001;49:110–113
Wiley Online Library
Show moreShow less
Save Cite Cited by 69 Related articles All 6 versions